SCHEMBL1300386

SCHEMBL1300386

O=C(O)c1cc(I)c(F)nc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.41
NFE2L2 Q16236 1/20 0.41
NAPRT Q6XQN6 1/20 0.38
ASPH Q12797 3/20 0.37
KDM4E B2RXH2 2/20 0.37
KDM8 Q8N371 2/20 0.37
TPMT P51580 1/20 0.35
MAOB P27338 1/20 0.35
TP53 P04637 1/20 0.35
TTR P02766 1/20 0.35
ALB P02768 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
ALOX15 P16050 2/20 0.31
TSHR P16473 1/20 0.31
HIF1A Q16665 1/20 0.31
ALDH1A1 P00352 2/20 0.31
DHODH Q02127 1/20 0.31
GAA P10253 1/20 0.31
MAP2K2 P36507 1/20 0.31
MAP2K1 Q02750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3963655 0.78 KEAP1 (0.53) KEAP1NFE2L2NAPRTASPHKDM4E
SCHEMBL12413781 0.78 POLB (0.47) KEAP1NFE2L2KDM4ETPMTALDH1A1
SCHEMBL1300635 0.77 CFTR (0.46) KDM4ETSHRALDH1A1GAACYP1A2
SCHEMBL6837965 0.75 KDM4E (0.41) KEAP1NFE2L2NAPRTASPHKDM4E
SCHEMBL1301581 0.72 KEAP1 (0.39) KEAP1NFE2L2NAPRTASPHKDM4E
SCHEMBL1685590 0.71 TPMT (0.48) NAPRTKDM4ETPMTMAOBTP53
SCHEMBL3870844 0.71 KEAP1 (0.45) KEAP1NFE2L2ASPHKDM4EKDM8
SCHEMBL1562956 0.70 TPMT (0.38) KEAP1NFE2L2NAPRTASPHKDM4E
SCHEMBL19866316 0.70 TP53 (0.41) KEAP1NFE2L2ASPHKDM4EKDM8
SCHEMBL1045113 0.70 KDM4E (0.44) KEAP1NFE2L2ASPHKDM4EKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569484-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2013-10-29 US disclosed
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2012-05-17 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 US disclosed
US-20110178064-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL ASTRAZENECA R&D (SE) 2011-07-21 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 US disclosed
WO-2010136817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-12-02 WO disclosed
EP-2231665-A2 NOVEL COMPOSITIONS AND METHODS OF USE Ardea Biosciences, Inc. (US) 2010-09-29 EP disclosed
EP-2178876-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL AstraZeneca AB (SE) 2010-04-28 EP disclosed
WO-2009089263-A2 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES INC. (US) 2009-07-16 WO disclosed
WO-2009010801-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL ASTRAZENECA UK LIMITED (GB) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178064-A1 SPIRO CONDENSED BARBITURIC ACID DERIVATIVES FOR USE AS ANTIBACTERIAL TBCA, TUBA1A, BROX KEAP1 779/4885NFE2L2 631/4885NAPRT 1967/4885
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF UROD, UMPS, SLC14A1 KEAP1 2094/4885NFE2L2 1943/4885NAPRT 773/4885
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP KEAP1 3810/4885NFE2L2 4628/4885NAPRT 275/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP KEAP1 3810/4885NFE2L2 4628/4885NAPRT 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.